NASDAQ$PRCT
PROCEPT BioRobotics Corporation · Q3 2024 earnings
Q3 2024 earnings · · Investor relations
Briefing
Reported a successful quarter with strong revenue growth and record gross margins, driven by the launch of HYDROS and increased system sales.
PROCEPT BioRobotics reported a strong third quarter in 2024, with total revenue increasing by 66% compared to the prior year period. The company launched HYDROS, contributing to U.S. handpiece and consumables revenue growth of 74%. Gross margin reached a record 63.2%. The company increased its full year 2024 revenue and Adjusted EBITDA guidance.
- Total revenue for Q3 2024 reached $58.4 million, a 66% increase year-over-year.
- U.S. handpiece and consumables revenue grew by 74% to $29.6 million in Q3 2024.
- U.S. system and rental revenue increased by 46% to $19.6 million in Q3 2024.
- Gross margin improved to a record 63.2% in Q3 2024.
Headline financials
Revenue & EPS history
PROCEPT BioRobotics · Revenue · Quarterly
$58.4M
Revenue by segment
PROCEPT BioRobotics · $33M total across 4 segments · Q3 2023
- U.S. Consumables$17M+112.7%51.7%
- U.S. System Sales$13.5M+37.3%40.8%
- Intl. Consumables$1.65M+108.7%5.0%
- Intl. System Sales$828K+11.4%2.5%
Forward guidance
The Company projects revenue for the full year 2024 to be in the range of $222.5 million to $223.0 million. The Company projects full year 2024 gross margin to be approximately 61%. The Company projects full year 2024 total operating expense of approximately $231.5 million. The Company projects full year 2024 Adjusted EBITDA loss to be ($60.0) million.
Tailwinds
- Revenue for full year 2024 is projected to be between $222.5 million and $223.0 million, representing 63% and 64% growth respectively.
- Full year 2024 gross margin is projected to be approximately 61%.
- Full year 2024 Adjusted EBITDA loss is projected to be ($60.0) million.
- Revenue guidance increased from $217.0 million.
- Adjusted EBITDA loss guidance improved from ($67.5) million.
Headwinds
- Full year 2024 Adjusted EBITDA loss is projected to be ($60.0) million.
- Total operating expense for full year 2024 is projected to be approximately $231.5 million.
- All surgical treatments have inherent and associated side effects.
- Net loss for the third quarter of 2024 was $21.0 million.
- Operating expenses in the third quarter of 2024 were $59.3 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2024
+1.3%
Avg return
Earnings day
-0.2%
Avg return
5 days after
+0.6%
Avg return
30 days after
45%
10 / 22 earnings
Positive
+40.6%
Q3 2024
Best reaction
-15.2%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +10.7% | +16.0% | +21.3% | |
| Q4 2025 | -15.2% | -5.7% | -5.3% | |
| Q3 2025 | +1.6% | -7.5% | +2.7% | |
| Q1 2025 | -5.6% | +1.1% | +3.0% | |
| Q4 2024 | +8.6% | -3.4% | -4.2% | |
| Q3 2024 | +40.6% | +34.2% | +41.5% | |
| Q2 2024 | -9.4% | -4.3% | +24.8% | |
| Q1 2024 | +16.5% | +15.9% | +25.3% | |
| Q4 2023 | +1.1% | +0.5% | +1.2% | |
| Q3 2023 | +21.7% | +22.5% | +39.5% | |
| Q2 2023 | -6.7% | -10.3% | -18.4% | |
| Q1 2023 | -15.0% | -20.1% | -10.9% | |
| Q4 2022 | +1.2% | -4.3% | -28.7% | |
| Q3 2022 | -9.9% | -8.4% | +5.8% | |
| Q2 2022 | +4.3% | +4.3% | +0.2% | |
| Q1 2022 | -5.1% | -17.9% | +19.5% | |
| Q4 2021 | +1.2% | +5.9% | +38.7% | |
| Q3 2020 | -2.2% | -4.5% | -28.0% | |
| Q4 2020 | -2.2% | -4.5% | -28.0% | |
| Q2 2021 | -2.2% | -4.5% | -28.0% | |
| Q1 2021 | -2.2% | -4.5% | -28.0% | |
| Q3 2021 | -4.4% | -3.9% | -29.6% | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro